Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 1992 Jan-Feb;107(1):47–53.

Some current factors influencing the prescribing and use of psychiatric drugs.

R L Poulsen 1
PMCID: PMC1403600  PMID: 1738808

Abstract

A reprise of selected known factors about the influences affecting the prescribing and use of drugs, and some new developments in the drug marketplace, are the basis for this summary and observations about future expectations regarding psychotherapeutic agents. This information can be used to assist in formulating or updating, or both, conceptualizations and hypotheses for future policy and research planning in this area.

Full text

PDF
52

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldessarini R. J., Cohen B. M. Regulation of psychiatric practice. Am J Psychiatry. 1986 Jun;143(6):750–751. doi: 10.1176/ajp.143.6.750. [DOI] [PubMed] [Google Scholar]
  2. Bloom M. Z. Clinical pharmacy services improve patient care and reduce costs. Am Pharm. 1990 Apr;NS30(4):17–18. doi: 10.1016/s0160-3450(15)31504-x. [DOI] [PubMed] [Google Scholar]
  3. Brill H. Notes on the history of social psychiatry. Compr Psychiatry. 1980 Nov-Dec;21(6):492–499. doi: 10.1016/0010-440x(80)90052-8. [DOI] [PubMed] [Google Scholar]
  4. Eisenberg L. A research framework for evaluating the promotion of mental health and prevention of mental illness. Public Health Rep. 1981 Jan-Feb;96(1):3–19. [PMC free article] [PubMed] [Google Scholar]
  5. Falk W. E., Eisenthal S., Erman M. K. Psychiatrists and their prescribing practices. Compr Psychiatry. 1985 Nov-Dec;26(6):548–553. doi: 10.1016/0010-440x(85)90021-5. [DOI] [PubMed] [Google Scholar]
  6. Freedman J. Psychotropic drugs and the right to refuse treatment. Hosp Community Psychiatry. 1981 Oct;32(10):732–733. doi: 10.1176/ps.32.10.732. [DOI] [PubMed] [Google Scholar]
  7. Gans J. A. APhA's new CEO. An interview with John A. Gans. Interview by Marlene Z. Bloom. Am Pharm. 1989 Oct;NS29(10):25–28. [PubMed] [Google Scholar]
  8. Gutheil T. G. The psychology of psychopharmacology. Bull Menninger Clin. 1982 Jul;46(4):321–330. [PubMed] [Google Scholar]
  9. Hemminki E. Problems of clinical trials as evidence of therapeutic effectiveness. Soc Sci Med. 1982;16(6):711–712. doi: 10.1016/0277-9536(82)90461-0. [DOI] [PubMed] [Google Scholar]
  10. Kane J. M., Smith J. M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982 Apr;39(4):473–481. doi: 10.1001/archpsyc.1982.04290040069010. [DOI] [PubMed] [Google Scholar]
  11. Karasu T. B. Psychotherapy and pharmacotherapy: toward an integrative model. Am J Psychiatry. 1982 Sep;139(9):1102–1113. doi: 10.1176/ajp.139.9.1102. [DOI] [PubMed] [Google Scholar]
  12. Keith S. J. Drugs: not the only treatment. Hosp Community Psychiatry. 1982 Oct;33(10):793–793. doi: 10.1176/ps.33.10.793. [DOI] [PubMed] [Google Scholar]
  13. Lipman R. S., Rickels K., Uhlenhuth E. H., Park L. C., Fisher S. Neurotics who fail to take their drugs. Br J Psychiatry. 1965 Nov;111(480):1043–1049. doi: 10.1192/bjp.111.480.1043. [DOI] [PubMed] [Google Scholar]
  14. Reich W. Psychiatry's second coming. Psychiatry. 1982 Aug;45(3):189–196. doi: 10.1080/00332747.1982.11024150. [DOI] [PubMed] [Google Scholar]
  15. Senay E. C. Addictive behaviors and benzodiazepines: 1. Abuse liability and physical dependence. Adv Alcohol Subst Abuse. 1989;8(1):107–124. doi: 10.1300/J251v08n01_08. [DOI] [PubMed] [Google Scholar]
  16. Shulman S. R. The broader message of accutane. Am J Public Health. 1989 Nov;79(11):1565–1568. doi: 10.2105/ajph.79.11.1565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Swartz M., Landerman R., George L. K., Melville M. L., Blazer D., Smith K. Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. Am J Public Health. 1991 May;81(5):592–596. doi: 10.2105/ajph.81.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Trinkoff A. M., Anthony J. C., Muñoz A. Predictors of the initiation of psychotherapeutic medicine use. Am J Public Health. 1990 Jan;80(1):61–65. doi: 10.2105/ajph.80.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Westermeyer J. Treatment for psychoactive substance use disorder in special populations: issues in strategic planning. Adv Alcohol Subst Abuse. 1990;8(3-4):1–8. doi: 10.1300/J251v08n03_01. [DOI] [PubMed] [Google Scholar]
  20. Williams P. The cost of tranquilizers. Soc Sci Med. 1982;16(22):1955–1958. doi: 10.1016/0277-9536(82)90398-7. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES